Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tandutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 19/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 7/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 6/20 | 1.00 |
| ▸ | CSF1R | P07333 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tandutinib SCHEMBL29393910 | 1.00 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| Tandutinib SCHEMBL2478362 | 0.99 | PDGFRB (0.98) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13330466 | 0.99 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| Tandutinib SCHEMBL2496722 | 0.96 | PDGFRB (0.93) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13330462 | 0.96 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13524739 | 0.94 | PDGFRB (0.90) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13529590 | 0.93 | PDGFRB (0.89) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL13330482 | 0.93 | PDGFRB (0.88) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL29460355 | 0.93 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 | |
| SCHEMBL317630 | 0.93 | PDGFRB (1.00) | PDGFRBFLT3KITCSF1RPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2602 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260142007-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) | REMEPY HEALTH LTD (IL) | 2026-05-21 | — | — | US | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4731220-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Dana Farber Cancer Institute, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| US-20250333795-A1 | COMPOSITION FOR AMPLIFYING FLT3 GENE, AND USES THEREOF | NGENEBIO (KR) | 2025-10-30 | — | — | US | claimed |
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-09-11 | — | — | US | claimed |
| US-20250213497-A1 | A NANO IN MICRO FORMULATION AND PROCESS THEREOF | AMRITA VISHWA VIDYAPEETHAM (IN) | 2025-07-03 | — | — | US | claimed |
| EP-4578962-A1 | COMPOSITION FOR AMPLIFYING FLT3 GENE, AND USES THEREOF | Ngenebio (KR) | 2025-07-02 | — | — | EP | claimed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | claimed |
| EP-2638896-A1 | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood | Bioneer A/S (DK) | 2013-09-18 | — | — | EP | claimed |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-12-01 | — | — | US | claimed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | claimed |
| EP-1949902-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | claimed |
| JP-2005533604-A | — | — | 2005-11-10 | — | — | JP | claimed |
| US-20050203612-A1 | Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia | AVANTEC VASCULAR CORPORATION (US) | 2005-09-15 | — | — | US | claimed |
| EP-1539041-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | Avantec Vascular Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |